1. Scrip

Kyowa Kirin links with Ultragenyx for first-in-class XLH therapy

 
• By Ian Haydock

Kyowa Hakko Kirin is tapping the specialist expertise of the private US venture Ultragenyx Pharmaceutical to speed up the development and commercialization of potentially the first specific therapy for the rare metabolic bone disorder X-linked hyperphosphatemia (XLH).

Kyowa Hakko Kirin is tapping the specialist expertise of the private US venture Ultragenyx Pharmaceutical to speed up the development and commercialization of potentially the first specific therapy for the rare metabolic bone disorder X-linked hyperphosphatemia (XLH).

The IgG1 monoclonal antibody KRN23, discovered by the Japanese firm, is currently in the latter stages of a Phase I/II...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?